{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:52:51Z","timestamp":1787032371177,"version":"build-2736575974"},"reference-count":196,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma are the most common aggressive pediatric mature B-cell non-Hodgkin lymphomas (B-NHLs). Despite excellent survival with current chemotherapy regimens, therapy for Burkitt lymphoma and DLBCL has a high incidence of short- and long-term toxicities. Patients who experience relapse generally have a very poor prognosis. Therefore, novel approaches using targeted therapies to reduce toxicities and improve outcomes in the relapse setting are needed. The addition of rituximab, a monoclonal antibody against CD20, to upfront therapy has improved survival outcomes for high-risk patients and may allow decreased total chemotherapy in those with low-risk disease. Antibody\u2013drug conjugates have been combined with chemotherapy in relapsed\/refractory (R\/R) NHL, and multiple antibody\u2013drug conjugates are in development. Additionally, bispecific T-cell\u2013engaging antibody constructs and autologous CAR T-cells have been successful in the treatment of R\/R acute leukemias and are now being applied to R\/R B-NHL with some successes. PD-L1 and PD-L2 on tumor cells can be targeted with checkpoint inhibitors, which restore T-cell\u2013mediated immunity and antitumor responses and can be added to conventional chemotherapy and immune-directed therapies to augment responses. Lastly, trials of small molecule inhibitors targeting cell signaling pathways in NHL subtypes are underway. This article reviews many of the targeted therapies under development that could be considered for future trials in R\/R pediatric mature B-NHL.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7608","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T15:25:28Z","timestamp":1596641128000},"page":"1125-1134","source":"Crossref","is-referenced-by-count":21,"title":["Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.6004","volume":"18","author":[{"given":"Paul D.","family":"Harker-Murray","sequence":"first","affiliation":[{"name":"1Pediatric Oncology, Midwest Children's Cancer Center, Milwaukee, Wisconsin; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pommert","sequence":"additional","affiliation":[{"name":"1Pediatric Oncology, Midwest Children's Cancer Center, Milwaukee, Wisconsin; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Barth","sequence":"additional","affiliation":[{"name":"2Roswell Park Cancer Institute, Buffalo, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref631","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"ref781","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113744","article-title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells [abstract]","volume":"132","author":"Rivers","year":"2018","journal-title":"Blood"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref1121","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15520","article-title":"Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB\/LMB96 and COG ANHL01P1","volume":"185","author":"Frazer","year":"2019","journal-title":"Br J Haematol"},{"key":"ref201","article-title":"Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20+ mature B\u2010cell lymphoma [abstract]","volume":"182","author":"Goldman","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1354750X.2019.1691656","article-title":"Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution","volume":"25","author":"Salas","year":"2020","journal-title":"Biomarkers"},{"key":"ref61","article-title":"The spectrum of MYC alterations in diffuse large B-cell lymphoma [published online February 19, 2020]","author":"Xia","journal-title":"Acta Haematol"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"21820","DOI":"10.18632\/oncotarget.25072","article-title":"Pre-clinical activity of targeting the PI3K\/Akt\/mTOR pathway in Burkitt lymphoma","volume":"9","author":"Bhatti","year":"2018","journal-title":"Oncotarget"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised International Pediatric Non-Hodgkin Lymphoma Staging System","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref01","volume-title":"Principles and Practice of Pediatric Oncology","author":"Pizzo","year":"2015"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1701","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL) [abstract]","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1801","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113744","article-title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells [abstract]","volume":"132","author":"Rivers","year":"2018","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/10428194.2016.1207764","article-title":"Ofatumumab monotherapy in relapsed\/refractory diffuse large B-cell non-Hodgkin lymphoma","volume":"58","author":"Galanina","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br J Haematol"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96 mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3324\/haematol.2016.156885","article-title":"Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-M\u00fcnster protocols","volume":"102","author":"Rohde","year":"2017","journal-title":"Haematologica"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2018.07.001","article-title":"The unique biology and treatment of primary mediastinal B-cell lymphoma","volume":"31","author":"Broccoli","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref661","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) [abstract]","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjh.15734","article-title":"Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies","volume":"185","author":"Egan","year":"2019","journal-title":"Br J Haematol"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V120.21.3692.3692","article-title":"Phase I\/II trial of ofatumumab\/lenalidomide for patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: high response rate in indolent lymphoma","volume":"120","author":"Vose","year":"2012","journal-title":"Blood"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjh.15734","article-title":"Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies","volume":"185","author":"Egan","year":"2019","journal-title":"Br J Haematol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11912-020-0875-2","article-title":"Immunotherapy for the treatment of acute lymphoblastic leukemia","volume":"22","author":"Barsan","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.19.02587","article-title":"Polatuzumab vedotin: honing in on relapsed or refractory diffuse large B-cell Lymphoma","volume":"38","author":"Shingleton","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref321","first-page":"412","article-title":"Safety and efficacy of myeloablative conditioning autologous stem cell transplantation targeted immunotherapy and reduced intensity conditioning allogeneic stem cell transplantation in children adolescents and young adults with relapsed \/ refractory mature","volume":"25","author":"GardenswartzA","year":"2019","journal-title":"Biol"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref1791","article-title":"Early response observed in pediatric patients with refractory\/relapsed B-cell non-Hodgkin lymphoma treated with sequential chimeric antigen receptor T cells [abstract]","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/10428194.2016.1207764","article-title":"Ofatumumab monotherapy in relapsed\/refractory diffuse large B-cell non-Hodgkin lymphoma","volume":"58","author":"Galanina","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref451","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111279","article-title":"Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed\/refractory classical Hodgkin lymphoma [abstract]","volume":"132","author":"Harker-Murray","year":"2018","journal-title":"Blood"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br J Haematol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"ref1851","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1777.1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110\u03b4, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]","volume":"116","author":"Kahl","year":"2010","journal-title":"Blood"},{"key":"ref1221","article-title":"Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20+ mature B\u2010cell lymphoma [abstract]","volume":"182","author":"Goldman","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2018.07.001","article-title":"The unique biology and treatment of primary mediastinal B-cell lymphoma","volume":"31","author":"Broccoli","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V120.21.3692.3692","article-title":"Phase I\/II trial of ofatumumab\/lenalidomide for patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: high response rate in indolent lymphoma","volume":"120","author":"Vose","year":"2012","journal-title":"Blood"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11912-020-0875-2","article-title":"Immunotherapy for the treatment of acute lymphoblastic leukemia","volume":"22","author":"Barsan","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br J Haematol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib\/II study","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"ref751","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128203","article-title":"Initial findings of the phase 1 trial of PBCAR0191, a CD19 targeted allogeneic CAR-T cell therapy [abstract]","volume":"134","author":"Jacobson","year":"2019","journal-title":"Blood"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised International Pediatric Non-Hodgkin Lymphoma Staging System","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15520","article-title":"Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB\/LMB96 and COG ANHL01P1","volume":"185","author":"Frazer","year":"2019","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van Imhoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.bbmt.2019.07.041","article-title":"Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma","volume":"25","author":"Herrera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2018-02-778480","article-title":"Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective","volume":"132","author":"Dunleavy","year":"2018","journal-title":"Blood"},{"key":"ref101","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"key":"ref1771","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128203","article-title":"Initial findings of the phase 1 trial of PBCAR0191, a CD19 targeted allogeneic CAR-T cell therapy [abstract]","volume":"134","author":"Jacobson","year":"2019","journal-title":"Blood"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/1354750X.2019.1691656","article-title":"Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution","volume":"25","author":"Salas","year":"2020","journal-title":"Biomarkers"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"ref831","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1777.1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110\u03b4, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]","volume":"116","author":"Kahl","year":"2010","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjh.13969","article-title":"Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children","volume":"173","author":"Giulino-Roth","year":"2016","journal-title":"Br J Haematol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"e27873","DOI":"10.1002\/pbc.27873","article-title":"Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study","volume":"66","author":"Rigaud","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"21820","DOI":"10.18632\/oncotarget.25072","article-title":"Pre-clinical activity of targeting the PI3K\/Akt\/mTOR pathway in Burkitt lymphoma","volume":"9","author":"Bhatti","year":"2018","journal-title":"Oncotarget"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96 mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"key":"ref1471","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111279","article-title":"Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed\/refractory classical Hodgkin lymphoma [abstract]","volume":"132","author":"Harker-Murray","year":"2018","journal-title":"Blood"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"ref1761","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125102","article-title":"CD20 targeted CAR-T for high-risk B-cell non-Hodgkin lymphomas [abstract]","volume":"134","author":"Shadman","year":"2019","journal-title":"Blood"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"ref771","article-title":"Early response observed in pediatric patients with refractory\/relapsed B-cell non-Hodgkin lymphoma treated with sequential chimeric antigen receptor T cells [abstract]","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1021","volume-title":"Principles and Practice of Pediatric Oncology","author":"Pizzo","year":"2015"},{"key":"ref681","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL) [abstract]","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjh.13969","article-title":"Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children","volume":"173","author":"Giulino-Roth","year":"2016","journal-title":"Br J Haematol"},{"key":"ref1341","first-page":"412","article-title":"Safety and efficacy of myeloablative conditioning autologous stem cell transplantation targeted immunotherapy and reduced intensity conditioning allogeneic stem cell transplantation in children adolescents and young adults with relapsed \/ refractory mature","volume":"25","author":"GardenswartzA","year":"2019","journal-title":"Biol"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.bbmt.2019.07.041","article-title":"Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma","volume":"25","author":"Herrera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3109\/10428194.2012.677534","article-title":"Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia","volume":"53","author":"Anoop","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.19.02587","article-title":"Polatuzumab vedotin: honing in on relapsed or refractory diffuse large B-cell Lymphoma","volume":"38","author":"Shingleton","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","article-title":"Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib\/II study","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br J Haematol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint inhibitors Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"ref1081","article-title":"The spectrum of MYC alterations in diffuse large B-cell lymphoma [published online February 19, 2020]","author":"Xia","journal-title":"Acta Haematol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3324\/haematol.2016.156885","article-title":"Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-M\u00fcnster protocols","volume":"102","author":"Rohde","year":"2017","journal-title":"Haematologica"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref741","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125102","article-title":"CD20 targeted CAR-T for high-risk B-cell non-Hodgkin lymphomas [abstract]","volume":"134","author":"Shadman","year":"2019","journal-title":"Blood"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"e27873","DOI":"10.1002\/pbc.27873","article-title":"Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study","volume":"66","author":"Rigaud","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3109\/10428194.2015.1017821","article-title":"A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"56","author":"Wagner-Johnston","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3109\/10428194.2015.1017821","article-title":"A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"56","author":"Wagner-Johnston","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","author":"Giulino-Roth","year":"2018","journal-title":"Blood"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint inhibitors Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","author":"Giulino-Roth","year":"2018","journal-title":"Blood"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"ref1681","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) [abstract]","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1125.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/8\/article-p1125.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:38:59Z","timestamp":1602855539000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1125.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":196,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7608","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}